FOSUN INTL (00656.HK) released its full-year 2025 financial results on March 30, revealing a stark structural outcome. Impacted by significant non-operating asset impairments, the group recorded its largest net loss attributable to shareholders since listing, amounting to RMB 23.396 billion. However, its core industrial operations remained stable, demonstrating the effectiveness of its dual-drive strategy of globalization and innovation.
"This performance is unprecedented in FOSUN's more than thirty-year history," admitted Chairman Guo Guangchang in his letter to shareholders. "Although the loss is primarily non-cash, the failure to meet profit expectations leads me, as Chairman and founder, to offer my sincere apologies to all shareholders and partners concerned with FOSUN's development."
Confronting this challenging situation, Guo Guangchang and the management team outlined FOSUN INTL's medium-term financial targets during the earnings presentation. The goals include striving to gradually restore annual profit to a scale of tens of billions of RMB, targeting the recovery of RMB 60 billion in funds at the group level, reducing total group debt to below RMB 60 billion, and aiming to achieve an investment-grade credit rating.
These results reflect both the concentrated pains of a transitional period and a critical juncture in FOSUN's strategy of "slimming down, strengthening the core, and focusing on main businesses." They signal the departure of this established industrial investment group from a "big and comprehensive" scale-expansion model. While shedding burdens represents a rebirth, the path from a RMB 23.396 billion loss to a RMB 10 billion profit remains fraught with challenges.
The substantial impairments led to the largest historical loss. For the full year 2025, FOSUN INTL reported total revenue of RMB 173.43 billion, a decrease of 9.7% year-on-year. The net loss attributable to shareholders was RMB 23.396 billion, widening from the RMB 4.35 billion loss in 2024.
The company had previously indicated in an earnings warning that one-off, non-cash impairment charges and value reassessments on certain assets were the primary reasons for the significant book loss in the 2025 financial statements.
Specifically, the continued downturn in the real estate sector and weak market demand pressured the group's property business. Adhering to the prudence principle, the company recorded a substantial asset impairment provision for certain property projects showing signs of devaluation. The group stated it would dynamically adjust its operational and sales strategies based on market conditions, actively seize opportunities, intensify marketing and inventory reduction efforts, and accelerate cash recovery. Additionally, due to market changes, the company impaired goodwill and intangible assets in certain non-core business segments to reflect their value objectively.
The total non-cash impairment amounted to RMB 23.4 billion. Approximately 55% stemmed from property project impairments, mainly related to Yuyuan Tourist Mart, which consequently reported a net loss of RMB 4.9 billion for 2025 (compared to a net profit of RMB 130 million in 2024). Goodwill and intangible asset impairments in non-core businesses accounted for about 45%, primarily from impairments on Baihe Jiayuan and St Hubert.
Management emphasized that this provision was a prudent accounting measure, not indicative of operational failures, and would not affect the company's daily operations, cash flow, or business activities. Core businesses such as pharmaceuticals and insurance continue to demonstrate stable growth.
The concentration of core businesses continues to increase. The top four subsidiaries—Fosun Pharma, Yuyuan Tourist Mart, Fidelidade (Portugal), and Fosun Tourism Group—collectively generated revenue of RMB 128.2 billion, accounting for 74% of the group's total revenue, a 3 percentage point increase year-on-year. This highlights a clearer focus on main businesses, gradually overcoming the fragmentation caused by past diversified expansion. Adjusted industrial operating profit for 2025 reached RMB 4 billion, indicating that core operations remain profitable.
The innovation and globalization strategies have yielded significant results. Overseas revenue grew to RMB 94.86 billion in 2025, representing 54.7% of total revenue, a 5.4 percentage point increase year-on-year. This global footprint effectively hedges against cyclical risks in any single domestic market and enhances overall risk resilience.
Guo Guangchang stated that this solid foundation provides the confidence and determination for the proactive choice to "repair the roof while the sun shines"—to shed burdens now, decisively exit underperforming assets that fail to meet value targets, and concentrate resources on high-growth core sectors. The focus is on deepening and strengthening core businesses to steer the company towards a leaner, healthier, and more sustainable development path.
"There will be short-term pains, but this is the path FOSUN must take to progress more steadily and further in the next phase," Guo emphasized. He believes that, in the long run, this impairment marks FOSUN's entry into a new development stage, and future operating results will more accurately reflect the quality of its core industrial operations post the significant write-down.
This strategic clearance stems from FOSUN's aggressive decades-long pursuit of diversification. Starting in 1992, Guo Guangchang and four other founders established Guangxin Technology with RMB 38,000, beginning with market research before venturing into biopharmaceuticals with the founding of Fosun Industrial (later Fosun Pharma). After its listing on the Shanghai Stock Exchange in 1998, FOSUN acquired a 20% stake in Yuyuan Tourist Mart in 2001, marking its initial foray into consumer retail. Acquisitions between 2002 and 2004, including companies like Yaopharma, signaled the early锋芒 of its diversified layout.
The 2007 listing of FOSUN INTL in Hong Kong, raising HKD 12.8 billion, was a major milestone for its diversification and global expansion. In 2010, FOSUN acquired a 7.1% stake in Club Med, its first overseas tourism acquisition, later increasing its stake to become the largest shareholder—a classic case of global M&A.
Over the next decade, FOSUN's diversified portfolio expanded rapidly, forming four major business ecosystems: Health, Happiness, Wealth, and智造 (Intelligent Manufacturing). Its reach extended to dozens of sectors including pharmaceuticals, tourism, consumer goods, insurance, intelligent manufacturing, real estate, and asset management, covering core areas of民生 consumption and industrial development.
In the consumer sector, FOSUN controls Shede Spirits and Jinhuijiu, with investments in gold jewelry and fashion brands. In finance, it acquired Fidelidade and expanded into domestic life and health insurance. In intelligent manufacturing, acquisitions like German FFT and Wansheng Advanced Materials targeted smart manufacturing and new materials. Real estate and asset management became key sectors for capital operation and asset allocation.
By 2022, FOSUN's global footprint peaked, with total assets exceeding RMB 830 billion, operations in over 30 countries and regions, and numerous listed companies, establishing it as a quintessential diversified industrial investment group in China.
The core of FOSUN's expansion relied on a dual-drive model of "industrial operation + investment," aiming to rapidly acquire assets, technology, and brands through M&A, then achieve synergy across sectors through industrial operations. However, rapid expansion led to a "big and comprehensive" asset structure. Some cross-sector investments lacked sufficient industrial synergy, and factors like misjudged industry cycles and management limitations caused some assets to become inefficient. As macroeconomic conditions shifted and industry cycles adjusted, these issues surfaced, exposing the drawbacks of over-diversification.
Starting in 2022, Guo Guangchang initiated the "slimming down and focusing on the core" strategy, significantly exiting heavy-asset and non-core businesses. By the end of 2025, FOSUN INTL's total assets stood at RMB 716.229 billion, down 10.1% from the end of 2024.
"In the past, FOSUN was particularly bold, making many attempts—some successful, some failed—and overall, we paid considerable tuition fees," Guo conceded in the 2025 annual report. "Looking back, there is indeed a value discrepancy between some of our past investments and the current market conditions compared to our initial expectations."
An analysis of the 2025 performance across business segments reveals significant disparities resulting from the aggressive diversification. The Health and Wealth segments, bolstered by deep industrial foundations and stable cash flows, served as dual pillars. In contrast, the Happiness and Intelligent Manufacturing segments, affected by industry cycles and insufficient asset synergy, became drags on the group's performance.
The Health segment reported revenue of RMB 48 billion in 2025, up 3.1% year-on-year, with net profit attributable to shareholders surging 59.2% to RMB 1.435 billion. Core subsidiary Fosun Pharma achieved a net profit of RMB 3.371 billion, up 21.69%, maintaining double-digit growth for two consecutive years and acting as the group's performance anchor.
The Wealth segment, comprising insurance and asset management, generated revenue of RMB 55.86 billion, a slight increase of 1.4%. The insurance business performed notably well. Overseas core platform Fidelidade reported a net profit of €201 million, up 15.8%. Domestically, Fosun United Health Insurance and Fosun Sponsored Sino-US United Paramount saw net profits surge by 492% and 231.2% respectively. The insurance business, with its stable profits and cash flow, is a crucial buffer against cyclical fluctuations. Asset management revenue fell 30.1%, primarily due to the deconsolidation of HAL and declining revenue from the real estate downturn.
The Happiness segment reported revenue of RMB 64.75 billion, down 15.6%, with a net loss attributable to shareholders of RMB 9.067 billion, a 382.6% increase in loss compared to 2024. This was mainly due to losses at Yuyuan Tourist Mart and goodwill impairments related to Baihe Jiayuan and St Hubert. The Intelligent Manufacturing segment saw revenue plummet 50.3% to RMB 7.741 billion, with a loss of RMB 1.546 billion, a 146.7% increase in loss, primarily attributed to the deconsolidation of翌耀科技 and asset impairments at Wansheng Advanced Materials and捷威动力.
Overall, FOSUN INTL's total revenue declined by 9.7% in 2025, marking the second consecutive year of decline. The real estate and certain manufacturing businesses are expected to continue dragging on overall performance due to industry cycles, and optimizing the business structure will require time.
Simultaneously, FOSUN's core sectors face intensifying competition. In the innovative drug sector within Health, R&D investments by domestic and international pharmaceutical companies are escalating, leading to fierce competition. The insurance sector's domestic and international布局 faces regulatory adjustments and intense rivalry. The tourism and consumer sectors are influenced by the pace of consumption recovery and increasing homogenization within the industries. These factors demand continuous investment in R&D and channel resources to enhance core competitiveness.
Financially, the total debt burden remains high. Total debt stood at RMB 224.2 billion at the end of 2025, slightly higher than the previous year. Meanwhile, cash and bank balances decreased by RMB 45.247 billion to RMB 61.092 billion, indicating a contraction in cash reserves.
Addressing these challenges, management stated its commitment to focusing on core industries to drive medium-to-long-term value growth. Priorities include pursuing innovation and globalization for superior long-term value; leveraging the strong global insurance business, seen as a key pillar for future profit growth due to its healthy profit and cash flow; advancing the asset-light and globalized operations of the tourism segment to better leverage resources and achieve efficient development; and striving for upgrades and breakthroughs in quality assets and businesses like Yuyuan's gold jewelry, Shede Spirits, and Hainan Mining.
Management has set a clear medium-term target of achieving over RMB 10 billion in net profit attributable to shareholders. This will be pursued by accelerating the disposal of heavy-asset and non-core subsidiaries, optimizing the asset portfolio, reducing interest-bearing debt at the group level to below RMB 60 billion, and lowering financial expenses. The company will also actively explore opportunities for non-listed assets to access capital markets.
Following this one-off risk clearance, FOSUN INTL is shedding its historical burdens and moving towards a leaner, healthier, and more sustainable development stage. However, short-term transition pains persist, and the path forward requires continued effort. The resilience of its core businesses and the execution of its strategy will be critical for its eventual value recovery.
Comments